Shaping the future of biomarker research in breast cancer to ensure clinical relevance.
Each year, over 200,000 people are diagnosed with breast cancer in the United States. Although the use of biomarkers has the potential to guide preventive interventions and improve survival and quality of life, there have been few successes and many disappointments. In November 2005, the National Breast Cancer Coalition Fund convened a conference aimed at developing a patient-centred, strategic approach to breast cancer biomarker research. The consumers, clinicians, researchers, industry representatives and US regulators who served on the consensus panel developed a set of principles and recommendations to guide the field and ensure that biomarker research results in clinically important applications.
Hinestrosa
M Carolina
MC
National Breast Cancer Coalition Fund 1101 17th Street, NW, Suite 1300 Washington, DC 20036, USA. chinestrosa@stopbreastcancer.org
Dickersin
Kay
K
Klein
Pamela
P
Mayer
Musa
M
Noss
Karin
K
Slamon
Dennis
D
Sledge
George
G
Visco
Frances M
FM
D015415:Biomarkers / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000628:therapy; D015195:Drug Design; D005260:Female; D006287:Health Planning Guidelines; D006801:Humans; D011379:Prognosis; D012042:Registries; D012106:Research / Q000193:education / Q000331:legislation & jurisprudence; D018570:Risk Assessment
D015415:Biomarkers; D014408:Biomarkers, Tumor